The future of the quinolones

被引:64
作者
Andriole, VT [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA
关键词
D O I
10.2165/00003495-199958002-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review emphasises the advances in the development of newer quinolones: their broader antimicrobial activity particularly their increased activity against Pneumococcus and anaerobes; their longer half-life and tissue penetration including activity in cerebrospinal fluid; and their excellent efficacy in respiratory, intra-abdominal, pelvic, and skin and soft tissue infections. Also, considerable progress has been made in our understanding of the development of bacterial resistance to the newer quinolones. Additional advances in quinolone development are likely to provide better compounds for clinical use.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 58 条
[1]   Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes [J].
Aldridge, KE ;
Ashcraft, D ;
Bowman, KA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :484-487
[2]   Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes [J].
Aldridge, KE ;
Ashcraft, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :709-711
[3]  
Andriole V.T., 1988, QUINOLONES, P155
[4]   FUTURE-ROLE AND USES OF THE QUINOLONES [J].
ANDRIOLE, VT .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1994, 3 :S211-S215
[5]  
Andriole VT, 1998, QUINOLONES, 2ND EDITION, P417
[6]  
ANDRIOLE VT, 1996, CURRENT MED, P148
[7]  
ANDRIOLE VT, 1993, DRUGS S, V3, P1
[8]  
ANDRIOLE VT, 1998, INFECT DIS, P2775
[9]   CLINICAL ISOLATE OF CITROBACTER-FREUNDII HIGHLY RESISTANT TO NEW QUINOLONES [J].
AOYAMA, H ;
FUJIMAKI, K ;
SATO, K ;
FUJII, T ;
INOUE, M ;
HIRAI, K ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (06) :922-924
[10]  
APPLEBAUM PC, 1995, DRUGS S2, V49, P76